Letter by Wu Et Al Regarding Article, “Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis”
Zhenguo Wu,Wencheng Zhang,Jianmin Yang
DOI: https://doi.org/10.1161/circulationaha.120.053212
IF: 37.8
2021-01-01
Circulation
Abstract:HomeCirculationVol. 143, No. 19Letter by Wu et al Regarding Article, “Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessLetterPDF/EPUBLetter by Wu et al Regarding Article, “Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis” Zhenguo Wu, MD Wencheng Zhang, MD, PhD Jianmin YangMD, PhD Zhenguo WuZhenguo Wu The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan. Search for more papers by this author , Wencheng ZhangWencheng Zhang https://orcid.org/0000-0002-9416-6540 The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan. Search for more papers by this author , Jianmin YangJianmin Yang The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan. Search for more papers by this author Originally published10 May 2021https://doi.org/10.1161/CIRCULATIONAHA.120.053212Circulation. 2021;143:e919–e920To the Editor:We read with great interest the recent article by Jeon et al,1 in which they revealed that Ninj1 (nerve injury-induced protein-1) is a matrix metalloproteinase 9 substrate, and the absence of Ninj1 exerts a proinflammatory effect by enhancing mitogen-activated protein kinase signaling and blocking the phosphoinositide 3-kinase/protein kinase B pathway in macrophages. They further showed that soluble Ninj1-mimetic peptides acted as anti-inflammatory mediators of macrophages and attenuated monocyte recruitment and atherosclerosis. Their results showed the important role of the soluble form of an adhesion molecule as a therapeutic target for atherosclerosis. However, there are some aspects that, in our opinion, need further research.A previous study described that Ninj1 reduced leukocyte recruitment into lesion sites and exerted an anti-inflammatory effect,2 and another study showed Ninj1 mediated the activation of mitogen-activated protein kinase signaling and the inhibition of phosphoinositide 3-kinase/protein kinase B signaling,3 which were at opposite poles of this article. Therefore, more studies should be performed to explore the reason for the differences. In addition, a previous study showed that Ninj1 was expressed in endothelial cells and mediated endothelial dysfunction.3 It would be interesting to explore the function of endothelium-derived Ninj1 in atherosclerosis. Ninj1 also showed a high expression in hepatocellular carcinoma4 and exerted its oncogenic function by repressing p53-dependent growth suppression.5 Thus, the safety of soluble Ninj1-mimetic peptides in treating atherosclerosis also needs further research.Disclosures None.Footnoteshttps://www.ahajournals.org/journal/circReferences1. Jeon S, Kim TK, Jeong SJ, Jung IH, Kim N, Lee MN, Sonn SK, Seo S, Jin J, Kweon HY, et al.. Anti-inflammatory actions of soluble Ninjurin-1 ameliorate atherosclerosis.Circulation. 2020; 142:1736–1751. doi: 10.1161/CIRCULATIONAHA.120.046907LinkGoogle Scholar2. Ahn BJ, Le H, Shin MW, Bae SJ, Lee EJ, Wee HJ, Cha JH, Lee HJ, Lee HS, Kim JH, et al.. Ninjurin1 deficiency attenuates susceptibility of experimental autoimmune encephalomyelitis in mice.J Biol Chem. 2014; 289:3328–3338. doi: 10.1074/jbc.M113.498212CrossrefMedlineGoogle Scholar3. Wang X, Qin J, Zhang X, Peng Z, Ye K, Wu X, Yang X, Shi H, Zhao Z, Guo X, et al.. Functional blocking of Ninjurin1 as a strategy for protecting endothelial cells in diabetes mellitus.Clin Sci (Lond). 2018; 132:213–229. doi: 10.1042/CS20171273CrossrefMedlineGoogle Scholar4. Kim JW, Moon AR, Kim JH, Yoon SY, Oh GT, Choe YK, Choe IS. Up-regulation of ninjurin expression in human hepatocellular carcinoma associated with cirrhosis and chronic viral hepatitis.Mol Cells. 2001; 11:151–157.MedlineGoogle Scholar5. Cho SJ, Rossi A, Jung YS, Yan W, Liu G, Zhang J, Zhang M, Chen X. Ninjurin1, a target of p53, regulates p53 expression and p53-dependent cell survival, senescence, and radiation-induced mortality.Proc Natl Acad Sci U S A. 2013; 110:9362–9367. doi: 10.1073/pnas.1221242110CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails May 11, 2021Vol 143, Issue 19Article InformationMetrics Download: 133 © 2021 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.053212PMID: 33970674 Originally publishedMay 10, 2021 PDF download SubjectsAtherosclerosisPreeclampsia